

Table of Contents

OVERVIEW

- This product contains forecasts for antiretroviral drugs for Human Immunodeficiency Virus (HIV) across the seven major markets from 2010 to 2019. It has been designed for delivery in an excel data pack format, but for more detail about this disease area please see the accompanying Forecast Insight: HIV word document (DMHC2629).

- The associated report can be found under Latest Research in the Knowledge Center, through the search function or by contacting your sales representative.
- Please select the data pack option from the download menu at the side of the page to access the model.
- Introduction
- The number of antiretroviral drugs reaching sales over \$400m across the seven major markets (US, Japan, France, Germany, Italy, Spain, UK) will decline from ten in 2009 to six in 2019. The dominance of cross-class fixed dose combinations (FDCs) will make it increasingly difficult for stand-alone agents to penetrate the crowded HIV market. Datamonitor expects the FDC Truvada/rilpivirine to become the best-selling antiretroviral in HIV, reaching sales of \$3.5 billion in 2019. Shionogi's/GlaxoSmithKline's integrase inhibitor S/GSK1349572 will become the most successful stand-alone pipeline agent.
- Scope of this research
- Research and analysis highlights
- Key reasons to read this report

•Forecasting Methodology

- The forecasting model:
- General event information:
- Event selection and quantification:
- Event parameters:

•Disclaimer